5.95

0.67% -0.04

Taysha Gene Therapies Inc (TSHA)

Overview News Price History Option Chain Financials Discussions Forecast

Taysha Gene Therapies Inc stock is traded at $5.95, with a volume of 2.13M. It is down -0.67% in the last 24 hours and up +4.39% over the past month. Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

Previous Close:

$5.99

Open:

$5.9

24h Volume:

2.13M

Relative Volume:

0.71

Market Cap:

$1.90B

Revenue:

$7.47M

Net Income/Loss:

$-129.88M

P/E Ratio:

-15.02

EPS:

-0.3962

Net Cash Flow:

$-115.33M

1W Performance:

-9.30%

1M Performance:

+4.39%

6M Performance:

+30.77%

1Y Performance:

+102.38%

1-Day Range:

$5.716

$6.0063

1-Week Range:

$5.716

$6.75

52-Week Range:

$2.7106

$7.30

Taysha Gene Therapies Inc Stock (TSHA) Company Profile

Name

Taysha Gene Therapies Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

(214) 612-0000

Address

3000 PEGASUS PARK DRIVE, DALLAS

Employee

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

TSHA's Discussions on Twitter

Compare TSHA vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TSHA Taysha Gene Therapies Inc	5.95	2.05B	7.47M	-129.88M	-115.33M	-0.3962
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-21-25	Initiated	Raymond James	Strong Buy
Jul-11-25	Initiated	BofA Securities	Buy
Jun-27-24	Initiated	BMO Capital Markets	Outperform
Apr-09-24	Initiated	Piper Sandler	Overweight
Feb-01-23	Downgrade	Jefferies	Buy → Hold
Jan-27-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-09-22	Downgrade	Goldman	Buy → Neutral
Mar-09-22	Initiated	Robert W. Baird	Outperform
Mar-01-22	Initiated	Wells Fargo	Overweight
Feb-18-22	Initiated	SMBC Nikko	Outperform
Dec-16-21	Initiated	Guggenheim	Buy
Jul-16-21	Initiated	Needham	Buy
Jun-24-21	Initiated	Truist	Buy
Jun-15-21	Initiated	BTIG Research	Buy
Jun-09-21	Initiated	Wedbush	Outperform
Jun-08-21	Initiated	JMP Securities	Mkt Outperform
May-19-21	Initiated	Cantor Fitzgerald	Overweight
May-11-21	Resumed	Jefferies	Buy
Feb-24-21	Initiated	William Blair	Outperform
Jan-05-21	Initiated	Oppenheimer	Outperform
Oct-19-20	Initiated	Chardan Capital Markets	Buy
Oct-19-20	Initiated	Goldman	Buy
Oct-19-20	Initiated	Jefferies	Buy
Oct-19-20	Initiated	Morgan Stanley	Overweight

View All

Taysha Gene Therapies Inc Stock (TSHA) Latest News

Aug 14, 2026

RA Capital reports 9.99% TSHA stake in Taysha Gene Therapies (TSHA) - Stock Titan

Aug 14, 2026

Aug 13, 2026

Morgan Stanley (TSHA holder) discloses 5.1% Taysha Gene Therapies stake in 13G/A - Stock Titan

Aug 13, 2026

Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.6%Here's Why - MarketBeat

Aug 13, 2026

Taysha Gene Therapies (TSHA) After Rett Trial Progress And Catalent Expansion Is The Undervalued Case Stronger - Yahoo Finance

Aug 13, 2026

Aug 12, 2026

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down Following Weak Earnings - MarketBeat

Aug 12, 2026

Why is Taysha Gene Therapies stock sliding today? By Investing.com - Investing.com Australia

Aug 12, 2026

Why is Taysha Gene Therapies stock sliding today? - Investing.com

Aug 12, 2026

Taysha Gene Therapies, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance

Aug 12, 2026

Taysha Gene Therapies, Inc. Stock 12‑Month Price Target Raised to $13.33, Implies 100% Upside - TradingView

Aug 12, 2026

Renaissance Technologies LLC Purchases 242,103 Shares of Taysha Gene Therapies, Inc. $TSHA - MarketBeat

Aug 12, 2026

TSHA SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus

Aug 12, 2026